Core Viewpoint - The acquisition of 20.31% stake in Guofu Quantum by Huajian Medical for approximately HKD 31.42 billion signifies a strategic move to enhance its business landscape and capitalize on the burgeoning RWA market [1][2]. Group 1: Strategic Considerations - The acquisition is driven by Huajian Medical's development needs and the trends in the RWA industry, which is projected to reach a market size of USD 16 trillion by 2030, accounting for 10% of global GDP [2]. - Huajian Medical aims to create a new growth curve through the establishment of the world's first innovative drug intellectual property RWA exchange, ivd.xyz, utilizing a "NewCo + RWA + stablecoin" model to tokenize high-value medical assets [2][3]. - The RWA technology allows for the segmentation of early-stage innovative drug pipeline assets into smaller tokens, broadening financing channels and improving efficiency [2]. Group 2: Market Opportunities - In the first half of 2025, China's innovative drug License-out total reached approximately USD 66 billion, surpassing the total BD transaction amount for 2024, indicating a significant opportunity for Huajian Medical's RWA business [3]. - Guofu Quantum, with its comprehensive financial licenses and expertise in quantum computing, AI, and blockchain, complements Huajian Medical's RWA strategy, addressing challenges such as the scarcity of financial licenses and expertise in digital assets [3][4]. Group 3: Business Synergy - The collaboration between Huajian Medical and Guofu Quantum is expected to create a complete ecosystem for the tokenization of innovative drug intellectual property, leveraging Huajian's medical industry resources and Guofu's financial technology capabilities [4]. - Huajian Medical can utilize Guofu Quantum's 22.5% stake in Southern Dongying to build a blockchain and financial technology-centric on-chain financial ecosystem, promoting asset tokenization and cross-border flow [4]. Group 4: Future Growth Potential - Post-acquisition, Huajian Medical is poised to expand its RWA asset types and enhance its market competitiveness by leveraging Guofu Quantum's resources [5][6]. - The partnership is expected to attract more enterprises into the RWA ecosystem, facilitating the tokenization of assets beyond innovative drugs and enhancing Huajian Medical's role as a bridge between Chinese assets and global capital [6][7]. - With the growing RWA market, Huajian Medical's unique position in the medical asset tokenization space, combined with its upgraded financial licenses and technical capabilities, positions it favorably for future competition [7]. Group 5: Conclusion - The acquisition represents a significant resource integration effort, aiming to reconstruct the link between finance and industry through RWA, with Huajian Medical potentially becoming a model for the digitalization of quality Chinese assets and compliant global capital allocation [8]. - The deepening synergy between the two companies may drive a new paradigm in the RWA industry, transitioning from single asset tokenization to a comprehensive ecosystem value co-creation [8].

Group 1 - The core point of the article is that Guofu Quantum (00290) has resumed trading with its stock price surging over 8% following the announcement of a significant share sale [1] - Guofu Quantum's largest shareholder, Liu Zhiwei, and shareholder Wang Tao will sell a total of 1.848 billion shares, representing approximately 20.31% of the company's issued share capital, to FINAL TOUCH LTD., a wholly-owned subsidiary of Huajian Medical, for HKD 3.142 billion [1] - After the transaction, Liu Zhiwei will no longer be the largest shareholder, and the buyer will become the new largest shareholder [1] Group 2 - Huajian Medical announced plans to collaborate with Guofu Quantum to build a comprehensive strategic synergy around "on-chain finance," focusing on the innovation and implementation of digital financial infrastructure [1] - The two companies will integrate technology, licenses, assets, and channel resources to create an efficient, compliant, and open platform for the issuance, trading, and management of on-chain assets, aiming to accelerate the digitization, fragmentation, and cross-border flow of traditional financial assets [1]

智通财经APP获悉，国富量子(00290)午后复牌，股价飙升逾8%。截至发稿，涨7.98%，报2.03港元，成 交额2435.89万港元。 华检医疗公告表示，展望未来，华检医疗将与国富量子围绕"链上金融"生态构建全面深化战略协同，共 同推动数字金融基础设施的创新与落地。双方将整合技术、牌照、资产与渠道资源，着力打造高效、合 规、开放的链上资产发行、交易及管理平台，加速实现传统金融资产的数字化、碎片化与跨境流动。 消息面上，国富量子公告，公司单一最大股东柳志伟及股东王涛将向华检医疗的全资附属公司FINAL TOUCH LTD.出售合共18.48亿股公司股份，占公司已发行股本约20.31%，代价为31.42亿港元。交易完 成后，柳志伟将不再是单一最大股东，而买方将成为公司的单一最大股东。国富量子董事会预计此变动 不会对公司日常营运产生重大不利影响。 ...

Core Viewpoint - A strategic acquisition valued at HKD 3.142 billion is reshaping China's global competitive landscape in the Real World Asset (RWA) tokenization sector [1] Group 1: Strategic Collaboration - The acquisition involves Huajian Medical acquiring approximately 1.848 billion shares of Guofu Quantum, representing 20.31% of the latter's issued share capital, for a total consideration of HKD 3.142 billion [1][4] - This transaction positions Huajian Medical as the largest shareholder of Guofu Quantum, which holds multiple financial licenses in Hong Kong, thereby creating a crucial bridge between traditional finance and Web3 on-chain finance [4][5] - The collaboration is expected to release significant synergies, combining Huajian Medical's leadership in medical testing equipment distribution with Guofu Quantum's comprehensive technology and financial investment platform [5] Group 2: Policy Alignment - The strategic move aligns with national policy directions aimed at fostering technological financial innovation, as outlined in a joint policy document by several Chinese government departments [6][7] - Recent regulatory advancements in Hong Kong, including the implementation of a stablecoin licensing regime, provide a clear compliance framework for RWA token issuance and trading [7] Group 3: Economic Impact - The acquisition's strategic value extends beyond commercial interests, aiming to enhance national innovation and public welfare by improving the liquidity of high-value medical assets through RWA tokenization [8] - The Chinese innovative drug transaction volume is projected to reach USD 60.8 billion in the first half of 2025, reflecting a 129% year-on-year increase, indicating growing global recognition of Chinese innovative drug assets [8] Group 4: Ecosystem Development - Huajian Medical is accelerating the establishment of an RWA exchange platform and on-chain financial ecosystem, including applying for a stablecoin license in the U.S. [9] - The company has initiated a strategic partnership with HashKey to enhance its Ethereum (ETH) treasury strategy, aiming to become a leading entity in ETH reserves within the Hong Kong and global markets [9] - The formation of the "Hong Kong Digital Asset Listed Companies Association" will support Huajian Medical's ecosystem expansion, connecting various stakeholders in the digital asset space [9] Group 5: Industry Growth - The RWA sector is transitioning from concept validation to large-scale application, with total locked value (TVL) in RWA reaching USD 12.5 billion by June 2025, a 124% increase from 2024 [9] - The market size surged from USD 8.6 billion to USD 23 billion in the first half of 2025, marking an increase of over 260% [9] Group 6: Strategic Significance - The partnership between Huajian Medical and Guofu Quantum signifies a critical step for China in the RWA infrastructure sector, potentially securing a first-mover advantage in global competition and enhancing the country's autonomous capabilities in digital financial infrastructure [10]

Group 1 - The largest shareholder of Guofu Quantum, Liu Zhiwei, along with shareholder Wang Tao, will sell a total of 1.848 billion shares, representing approximately 20.31% of the company's issued share capital, to FINAL TOUCH LTD., a wholly-owned subsidiary of Huajian Medical Holdings Limited, for HKD 3.142 billion [2] - After the transaction, Liu Zhiwei will no longer be the largest shareholder, and the buyer will become the single largest shareholder of the company [2] - The board of Guofu Quantum expects that this change will not have a significant adverse impact on the company's daily operations [2]

Core Viewpoint - The company, Guofu Quantum (00290), has announced a conditional sale agreement involving approximately 1.8485 billion shares, representing about 20.31% of its total issued share capital, for approximately HKD 3.142 billion [1] Group 1 - The largest shareholder, Dr. Liu Zhiwei, along with Mr. Wang Tao, will sell their shares to FINAL TOUCH LTD., a wholly-owned subsidiary of Huajian Medical (01931) [1][2] - Following the completion of the sale, Dr. Liu will hold approximately 8.8328 million shares (about 0.97% of the issued share capital), and Mr. Wang will hold approximately 9.0373 million shares (about 0.99% of the issued share capital) [2] - The buyer, Huajian Medical, will become the largest shareholder of the company after the transaction [2] Group 2 - The board anticipates that the sale and change in the largest shareholder will not have any significant adverse impact on the company's daily operations [2] - The company has applied to the Stock Exchange to resume trading of its shares from September 1, 2025, at 1:00 PM [2]

Group 1 - The company announced a conditional sale agreement involving approximately 1.8485 billion shares, representing about 20.31% of its total issued share capital, for a consideration of approximately HKD 3.142 billion [1] - Following the completion of the sale agreement, the largest shareholder will change, with the buyer, a wholly-owned subsidiary of Hua Jian Medical, becoming the single largest shareholder [2] - The board anticipates that the sale and change in the largest shareholder will not have any significant adverse impact on the company's daily operations [2] Group 2 - After the transaction, Dr. Liu Zhiwei will hold approximately 8.8328 million shares (about 0.97% of the issued share capital), and Mr. Wang will hold approximately 9.0373 million shares (about 0.99% of the issued share capital) [2] - The company has applied to the Stock Exchange to resume trading of its shares from September 1, 2025, at 1:00 PM [2]

格隆汇9月1日丨国富量子(00290.HK)公布，公司的股份(证券代号：00290)将于今天(1/9/2025)下午一时 正起恢复买卖。 ...

此外，公司已向联交所申请自2025年9月1日下午一时正起恢复公司股份买卖。 格隆汇9月1日丨国富量子(00290.HK)公布，公司获公司单一最大股东柳志伟及股东王涛分别告知，于 2025年9月1日，柳志伟连同AI International Capital ManagementLtd.(由柳志伟全资拥有)、Caitex Technology Holdings Limited(由淳大国际资本管理有限公司全资拥有，而淳大国际资本管理有限公司由 柳志伟全资拥有)及王涛(统称"卖方")已与FINAL TOUCH LTD.("买方")订立买卖协议，有条件出售合共 18.48亿股公司股份，相当于公告日期本公司已发行股本总数约20.31%，代价为31.42亿港元。买方为联 交所上市公司华检医疗控股有限公司(股份代号：1931)("华检医疗")的全资附属公司。 紧随买卖协议完成后，柳志伟将直接及间接持有合共8832.8万股股份(约占公司已发行股本0.97%)，且不 再为公司之单一最大股东，王涛将直接持有9037.30万股股份(约占公司已发行股本0.99%)，而买方及其 最终控股公司华检医疗将持有公司18.48亿股股份(约占公 ...

（前稱 GoFintech Innovation Limited 國富創新有限公司） （於開曼群島註冊成立之有限公司） 網址：https://290.com.hk （股份代號：290） 內幕消息 單一最大股東變動 及 恢復買賣 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GoFintech Quantum Innovation Limited 國富量子創新有限公司 陳健生 香港，二零二五年九月一日 本公告乃由國富量子創新有限公司（「本公司」）董事（「董事」）會（「董事會」）根據 香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條及香 港法例第571章證券及期貨條例第XIVA部之內幕消息條文（定義見上市規則）作出。 本公司獲本公司單一最大股東柳志偉博士（「柳博士」）及股東王濤先生（「王先生」） 分別告知，於二零二五年九月一日，柳博士連同AI International Capital Management Ltd.（由 ...